Pricing Log in Create free account
Friday 6 November 2026 Export ACAD’s income statement to Excel — free account

ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.

Revenue
+22.9%
EPS
−27.9%
Free cash flow
+141.2%

Quarter to September 2026, against a year earlier

21.23 0.01 −0.05%
Market cap
$3.7B
P/E
10.0×
Fwd P/E
33.4×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.46
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 5 2 3 1 1 1 — 1 —
Insider Ownership 1.45%

Capital & Financial Ratios $m

Size
Market Cap 3,660.00
Revenue ttm 1,202.30
Net income ttm 362.23
Free cash flow ttm 81.99
Net debt Q (976.45)
Valuation
P/E 9.97
Forward P/E 33.40
Price / sales 3.05
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.64
Financial health
Current ratio Q 3.82 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 0.00
Growth
Revenue growth Q +22.85% (above 0%: growing)
Operating income growth Q +100.58% (above 0%: growing)
EPS, this year −67.32% (below 0%: weak)
EPS, next year A +36.89% (at or above 15%: strong)
Revenue, next year A +18.71% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −11.92% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 7.3×; over the ten years it ranged from 1.8× in 2025 to 57,180× in 2016.
P/S against its own 10 years 6.60%
10-year low 10-year high
P/B against its own 10 years 0.95%
10-year low 10-year high
EV/Sales against its own 10 years 3.78%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 439 756 820 976
Receivables 102 105 148 178
Inventory 36 22 35 40
Other — — — —
616 938 1,062 1,268
2023 2024 2025 Q'26
Payables 18 16 11 16
ST’ Debt — — — —
Other — — — —
254 395 277 332

Compound Annual Growth %

10y 5y 3y
Sales 165.75% 19.39% 27.48%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 19.91% 14.38% 45.26%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.19 Actual 0.31

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.12 0.16 Beat by 0.04
Q1 FY26 0.04 0.02 Miss by 0.02
Q2 FY26 0.06 0.18 Beat by 0.12
Q3 FY26 0.19 0.31 Beat by 0.12
Q4 FY26 0.25 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.02 0.18 0.31 — —
’25 0.11 0.16 0.42 1.60 2.30
’24 0.10 0.20 0.20 0.86 1.36
’23 (0.27) 0.01 (0.40) 0.28 (0.37)
’22 (0.70) (0.21) (0.17) (0.26) (1.34)
’21 (0.42) (0.27) (0.09) (0.27) (1.05)
’20 (0.57) (0.27) (0.54) (0.42) (1.79)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 268 308 342 — —
’25 244 265 279 284 1,072
’24 206 242 250 260 958
’23 118 165 212 231 726
’22 115 135 131 136 517
’21 107 115 132 131 484
’20 90 110 121 121 442
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 34 101 12 — —
’25 20 64 74 (49) 110
’24 29 25 63 40 158
’23 (18) 8 (59) 85 17
’22 (76) (13) (1) (24) (114)
’21 (60) (25) (17) (23) (126)
’20 (49) (37) (23) (27) (136)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 29 96 10 — —
’25 (79) 64 (25) (53) 105
’24 29 25 63 40 157
’23 (18) (32) (59) 85 (23)
’22 (76) (13) (1) (24) (114)
’21 (61) (25) (17) (23) (127)
’20 (50) (40) (25) (29) (144)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 17 125 224 339 442 484 517 726 958 1,072 1,202 +58.1% 1,272 1,430 1,611 +14.6%
Gross margin, % 82.26 92.73 94.47 96.65 97.69 96.05 98.03 94.27 91.46 91.69 90.48 +9.4 pt
EBT (270) (288) (244) (234) (281) (168) (213) (51) 258 139 157 n/m
EBT margin, % (1,558.20) (230.81) (108.99) (69.12) (63.60) (34.60) (41.27) (7.03) 26.94 12.96 13.08 +1,571.2 pt
Net income (271) (289) (245) (235) (282) (168) (216) (61) 226 391 362 n/m
Per share, $
Per share, $ Revenue 0.15 1.02 1.77 2.30 2.81 3.02 3.20 4.43 5.78 6.36 6.97 +51.7%
Earnings (2.34) (2.36) (1.94) (1.60) (1.79) (1.05) (1.34) (0.37) 1.37 2.32 2.13 n/m
Cash flow (1.80) (1.78) (1.32) (1.03) (0.87) (0.78) (0.71) 0.10 0.95 0.65 0.57 n/m
Capex (0.08) (0.01) (0.02) (0.01) (0.05) (0.01) 0.00 (0.24) 0.00 (0.03) (0.09) (11.3%)
Free cash flow (1.88) (1.78) (1.34) (1.03) (0.91) (0.79) (0.71) (0.14) 0.95 0.62 0.48 n/m
Book value 4.47 2.73 3.78 4.75 3.99 3.37 2.48 2.64 4.42 7.29 8.04 +5.6%
Shares, m 116 123 127 147 157 160 162 164 166 168 171 +4.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.49 11.51 9.97 2.5
P/S 192.33 29.87 9.15 18.57 19.04 7.74 5.10 6.96 3.17 4.20 3.05 29.6
P/B 6.43 11.13 4.27 9.01 13.41 6.93 6.59 11.71 4.15 3.66 2.64 7.7
EV/Sales 161.81 27.14 7.03 16.52 17.61 6.66 4.30 6.36 2.39 3.43 2.23 25.3
EV/FCF (13.36) (15.51) (9.28) (36.78) (54.11) (25.44) (19.30) (197.73) 19.51 (39.55) (23.22) (39.2)
Cash, $m
Cash, $m Operating cash flow (208) (218) (167) (151) (136) (126) (114) 17 158 110 98 n/m
Capex (10) (1) (2) (1) (8) (1) — (40) (1) (5) (16) (7.5%)
Free cash flow (218) (219) (170) (152) (144) (127) (114) (23) 157 105 82 n/m
Balance, $m
Balance, $m Working capital 505 324 467 685 612 522 382 362 543 785 936 +5.0%
Net debt (529) (341) (474) (697) (632) (521) (417) (439) (756) (820) (976) +5.0%
Shareholders’ equity 518 335 479 699 627 541 400 432 733 1,227 1,387 +10.0%
Returns, %
Returns, % ROA (69.32) (61.21) (53.03) (35.55) (35.97) (22.64) (33.54) (9.17) 23.39 28.42 23.18 +97.7 pt
ROIC 0.00 0.00 (2,782.02) (9,032.28) 0.00 (527.66) 0.00 0.00 0.00 16.07 18.60 +16.1 pt
ROE (75.58) (67.80) (60.22) (39.93) (42.47) (28.75) (45.89) (14.73) 38.89 39.89 31.43 +115.5 pt
People
People Employees 370 425 430 503 601 514 513 598 654 798 — +8.9%
Revenue/emp, $m 0.05 0.29 0.52 0.67 0.74 0.94 1.01 1.21 1.46 1.34 — +45.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

ACADIA Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RLAY Relay Therapeutics, Inc. $3.7B — (loss-making) — (loss-making) −95.44% (below 0%: shrinking) n/m +2.13% (above 0%: growing) 100.00% (25,949.71%) Compare
ACAD ACADIA Pharmaceuticals Inc. $3.7B 10.0× 33.4× +22.85% (above 0%: growing) −27.91% (below 0%: shrinking) +141.15% (above 0%: growing) 89.75% 20.95%
XENE Xenon Pharmaceuticals Inc. $3.7B — (loss-making) — (loss-making) +100.70% (above 0%: growing) n/m −48.57% (below 0%: shrinking) 100.00% 0.00% Compare
TNGX Tango Therapeutics, Inc. $3.5B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −4.58% (below 0%: shrinking) 0.00% 0.00% Compare
IOVA Iovance Biotherapeutics, Inc. $3.5B — (loss-making) — (loss-making) +80.07% (above 0%: growing) n/m +89.72% (above 0%: growing) 0.00% (19.73%) Compare
IRON Disc Medicine, Inc. $3.5B — (loss-making) — — n/m +7.83% (above 0%: growing) 0.00% 0.00% Compare
PBLS Parabilis Medicines, Inc. $3.4B — (loss-making) — — n/m — 100.00% (34,382.43%) Compare
VKTX Viking Therapeutics, Inc. $3.3B — (loss-making) — — n/m −47.01% (below 0%: shrinking) 0.00% 0.00% Compare
DYN Dyne Therapeutics, Inc. $3.2B — (loss-making) — — n/m −39.08% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $3.5B — — −7.69% — −4.58% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 26.20%
Baker Bros. Advisors LP 25.40%
Julian C. Baker 25.40%
Stephen R. Biggar 25.40%
Blackrock Inc. 11.70%
The Vanguard Group 7.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ACADIA Pharmaceuticals Inc. (ACAD) Latest News

5 Nov

Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · Business Wire

21 Oct

Impact 4 · · Business Wire
Impact 3 · · Zacks

13 Oct

Impact 4 · · Zacks
Impact 3 · · MT Newswires

5 Oct

Impact 4 · · Simply Wall St.

29 Sep

Impact 4 · · Zacks

28 Sep

Impact 4 · · Business Wire

27 Sep

Impact 3 ·

25 Sep

Impact 4 · · Stocktwits
Impact 4 · · Zacks
Impact 3 · · clinicaltrialsarena.com

24 Sep

Impact 4 · · Insider Monkey
Impact 4 · · TIKR
Impact 4 · · Stocktwits
Impact 4 · · MarketBeat
Impact 4 · · MT Newswires
Impact 4 ·
Impact 3 · · Proactive Investors
Impact 3 · · InvestorsHub

24 Aug

Impact 4 ·
Impact 4 ·

12 Aug

Impact 4 · · MarketBeat

11 Aug

Impact 4 · · The Motley Fool transcript

10 Aug

Impact 3 ·

7 Aug

Impact 3 ·

ACAD metrics, ten years each

stockrow.com/ACAD · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com